Ikarovec

Ikarovec Limited is a pre-clinical gene therapy company dedicated to developing innovative treatments for common eye diseases, with a primary focus on Age-Related Macular Degeneration (AMD). Founded in 2018 as a spin-out from Quethera, the company is based at the Innovation Centre in Norwich, UK. Ikarovec aims to restore sight and prevent blindness through bi-functional gene therapies that provide long-term relief with a single injection, addressing the growing global AMD population. The company's core technology involves delivering genetic instructions to eye cells using AAV vectors, targeting multiple disease pathways simultaneously. This approach seeks to offer superior efficacy for chronic eye diseases like AMD. Ikarovec's pipeline is currently in the pre-clinical stage, focusing on AMD and other prevalent ophthalmic disorders. The leadership team includes experienced professionals with backgrounds in drug discovery and retinal therapies, supported by a global scientific advisory board.